EyeCyte Company

Caribou Biosciences is a biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins.
Caribou Biosciences has generated hundreds of thousands of data points from engineering many thousands of genomic sites across several different cell types. Our high throughput workflow relies on proprietary bioinformatics tools to design optimal guide RNAs for a given experiment. Engineered cells are then validated via next-generation sequencing and analysis of the modified genomic loci with custom analytical tools developed by our bioinformatics team.
Technology: Other
Industry: Regenerative Medicine
Headquarters: United States
Founded Date: 2005
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 1
Total Funding: $3M
Estimated Revenue: $1M to $10M
Last Funding Type: Series A

Visit Website
swaymire@eyecyte.com
Register and Claim Ownership